Latest market price
187.50
-5.81-3.01%
DVAQT68DaVita Inc.·NYSE
187.50-3.01%
News
Down 3.0% — DaVita Inc. 3rd Quarter 2026 Results (prnewswire.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E14.72EPS (ttm)12.74Insider Own—Shs Outstand63.80MPerf Week2.10%
Market Cap11.96BForward P/E11.15EPS next Y16.82Insider Trans-1.92%Shs Float62.48MPerf Month6.32%
Enterprise Value24.35BPEG2.32EPS next Q—Short Float7.85%Perf Quarter-19.76%
Income920.00MP/S0.84EPS this Y39.62%Short Ratio6.46Perf Half Y23.64%
Sales14.17BP/B10.62EPS next Y14.04%ROA5.16%Short Interest4.91MPerf YTD65.04%
Book/sh17.65P/C21.14EPS next 5Y7.10%ROE—52W High247.49 -24.24%Perf Year48.15%
Cash/sh8.87P/FCF9.25EPS past 3/5Y18.54% 8.28%ROIC10.69%52W Low101.00 85.64%Perf 3Y138.55%
Dividend Est.—EV/EBITDA8.70Sales past 3/5Y5.53% 3.39%Gross Margin30.96%Volatility4.59% 3.34%Perf 5Y62.18%
Dividend TTM—EV/Sales1.72EPS Y/Y TTM31.20%Oper. Margin14.85%ATR (14)7.29Perf 10Y206.87%
Dividend Ex-Date—Quick Ratio1.36Sales Y/Y TTM6.37%Profit Margin6.49%RSI (14)54.33Recom2.61
Dividend Gr. 3/5Y—Current Ratio1.41EPS Q/Q52.19%SMA202.67%Beta0.86Target Price235.67
Payout16.29%Debt/Eq11.50Sales Q/Q4.62%SMA503.36%Rel Volume2.15Prev Close193.31
Employees78,000LT Debt/Eq11.40EarningsFeb 01SMA2005.92%Avg Volume820.54KPrice187.50
IPO DateOct 31, 1995Option/ShortYes / YesEPS/Sales Surpr.6.86% 1.74%Net Debt/EBITDA4.42Volume1,760,622Change-3.01%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedOppenheimer$220
Aug-07-26ReiteratedRaymond JamesMarket Perform$220
Aug-07-26ReiteratedTruist SecuritiesHold$250 → $215
Aug-07-26UpgradeTD CowenHold → Buy
Aug-05-26ReiteratedDeutsche BankBuy$220 → $265
Aug-05-26ReiteratedBarclaysEqual Weight$218 → $224
Jul-14-26ReiteratedTruist SecuritiesHold$205 → $250
Jul-10-26ReiteratedUBSBuy$190 → $270
May-08-26ReiteratedTruist SecuritiesHold$158 → $205
May-06-26UpgradeDeutsche BankHold → Buy$220
Latest News· Times ET
Oct-30-26
Oct-29-26
Oct-28-26
Oct-27-26
Oct-23-26
Oct-22-26
Oct-21-26
Oct-20-26
Oct-19-26
Company

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue14,16813,64312,81612,140—————
Cost of Goods Sold Incl. D&A9,7819,9598,5998,320—————
Gross Profit4,3863,6844,2173,820—————
Selling, General and Administrative Excl. Other1,7261,6741,5381,474—————
Research and Development
0000—————
Other Operating Expense5560589744—————
Operating Income2,1032,0112,0901,603—————
Interest Expense559550470399—————
Unusual Expense
—————————
Non-Operating Income (Expense)-26-114-90-27—————
Net Income Before Taxes1,5181,3471,5301,177—————
Income Taxes324293280220—————
Consolidated Net Income920747936692—————
Net Income From Continuing Operations1,1931,0541,251957—————
Net Income920747936692—————
EPS (Recurring)13.039.7211.027.62—————
EPS (Basic, Before Extraordinaries)13.039.7211.027.62—————
EPS (Diluted)12.749.5110.737.42—————
EBITDA2,8002,6422,7252,321—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio14.7211.9513.9414.12—————
Price To Sales Ratio0.850.720.990.79—————
Gross Margin30.9627.0032.9031.47—————
Operating Margin14.8414.7416.3113.20—————
Net Margin6.495.487.305.70—————
Shares Outstanding64868591—————
Market Capitalization12,0009,77012,7129,533—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$261.52$216.97$172.42$127.86$83.31● Close Price0.00M50.03M100.07M150.10M200.13MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
BERKSHIRE HATHAWAY INC10% OwnerOct 27 '26Sale180.43382,56369,026,03328,314,666Oct 29
BERKSHIRE HATHAWAY INC10% OwnerJul 31 '26Sale199.55182,98036,513,29328,697,229Aug 04
Rodriguez JavierChief Executive OfficerJun 16 '26Sale209.2839,4078,247,018840,408Jun 17
Waters Kathleen AlyceChief Legal & Pub. Affairs OffJun 15 '26Sale208.4015,4053,210,377109,194Jun 17
Rodriguez JavierChief Executive OfficerJun 15 '26Sale209.5030,0006,285,090879,815Jun 17
HEARTY JAMES OChief Compliance OfficerMay 15 '26Sale193.9815,0002,909,74522,389May 18
HEARTY JAMES OChief Compliance OfficerMay 14 '26Option Exercise110.635,784639,88441,737May 18
Maughan David PaulChief Operating Officer, DKCMay 12 '26Sale199.2513,4562,681,16294,105May 13
Maughan David PaulChief Operating Officer, DKCMay 11 '26Sale199.157,0731,408,581107,561May 13
ACKERMAN JOELCFO and TreasurerMay 07 '26Sale192.1051,4719,887,528132,434May 11
HEARTY JAMES OChief Compliance OfficerMay 06 '26Sale174.872,184381,91635,953May 08
BERKSHIRE HATHAWAY INC10% OwnerMay 01 '26Sale149.841,220,376182,864,67928,880,209May 05
Waters Kathleen AlyceChief Legal & Pub. Affairs OffFeb 06 '26Option Exercise108.938,079880,045105,833Feb 09
ACKERMAN JOELCFO and TreasuerFeb 06 '26Option Exercise108.9344,0654,800,000185,705Feb 09
BERKSHIRE HATHAWAY INC10% OwnerJan 29 '26Sale120.561,658,480199,939,88130,100,585Feb 02
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.